Trump fast-tracks psychedelic drugs for mental healthcare use
The Trump administration signaled it will accelerate the FDA review process for psychedelic compounds like psilocybin and MDMA, targeting depression, PTSD and addiction treatment. The shift could broaden treatment options for veterans while creating opportunities for emerging biotech firms.
CNBC Top NewsAccording to CNBC, the Trump administration is showing explicit political backing for accelerating the regulatory pathway for psychedelic compounds previously classified as controlled substances. Health Secretary Robert F. Kennedy Jr and FDA Commissioner Marty Makary cited long-running clinical research into psilocybin and MDMA-based protocols for veteran mental health and treatment-resistant psychiatric conditions.
The move could lift shares of sector-representative firms such as ATAI Life Sciences, Compass Pathways and MindMed, although FDA officials emphasised the agency has not relaxed efficacy and safety standards. Researchers including Dr Caitlin Davis at Massachusetts General Brigham and Prof Roland Griffiths at Johns Hopkins flagged risks tied to use outside supervised clinical settings.
Washington's approach is drawing global attention as the European Medicines Agency launched a similar review cycle in 2025. Sector analysts cite forecasts that the US market could exceed $8 billion by 2030; the regulatory framework, insurance reimbursement and psychiatrist certification questions should clarify in coming months. This piece is not investment or medical advice.
More from North America
Broadcom shares plunge as software sales lag, AI chip forecast steady
Broadcom reported accelerating AI chip growth, but software sales lagged expectations and the full-year AI chip forecast was left unchanged. Shares fell sharply in after-hours trade. Investors questioned whether the unchanged guidance signals a slowdown in hyperscaler capital spending.
US House votes to constrain Trump's war powers on Iran
The US House of Representatives passed a resolution to restrict President Trump's authority to use military force against Iran without congressional approval. The measure now moves to the Senate, where its fate is uncertain; Trump is expected to veto if it reaches his desk. Oil markets traded volatile on the headline.
US private payrolls grew by 122,000 in May, stronger than expected, ADP reports
US private payrolls rose by 122,000 jobs in May, beating economists' expectations, according to the ADP report. The data suggests the labor market remains resilient as the Federal Reserve reassesses its interest-rate path.